Calmark recruits Director of International Business Development to develop global growth strategies
Calmark Sweden AB has signed an agreement with Magdalena Tharaldsen, who will be the company's new Director of International Business Development. Magdalena will be part of Calmark's Management Team and assumes responsibility for building the wide network of distributors that will provide the framework for Calmark's sales strategy.
Magdalena Tharaldsen has extensive experience from leading positions in life science companies; her most recent position was at MediRox AB, where she for five years had the same role as responsible for establishing new sales channels and developing new markets. Over the course of these years, the company has increased its turnover and now maintains a comprehensive distributor network across the most interesting global markets. Prior to that, Tharaldsen served at ALS Scandinavia, Attana and Recipharm, among other positions. Magdalena holds a M.Sc. in organic and analytical chemistry, and previously lived in England and Switzerland.
"It is truly inspiring and heartening to join the Calmark team and be able to make use of my experience in a new context," says Magdalena Tharaldsen. "The company develops important products in high demand, with a clear picture of its global objectives, and has reached an exciting stage."
"I take pride in the fact that we were able to recruit Magdalena for this key role," says Anna Söderlund, CEO of Calmark. "Her broad expertise and experience of building distributor networks in diagnostics will prove so valuable in our global expansion. I further wish to extend my gratitude to our current International Sales Director, Marianne Alksnis, as she now leaves us to take on new challenges."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first three tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags:
